Dapagliflozin-Sitagliptin in T2D: Moving Beyond HbA1c Towards a Broader Orbit of Care
Beyond HbA1c: Defining the Modern Treatment Goals in T2D Contemporary T2D management is no longer defined by achieving HbA1c targets alone. The ADA Standards of Care 2026 advocate a person centred approach, recommending that therapeutic decisions be guided by individualized glycaemic and weight goals, the…